These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17674545)

  • 21. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
    Mabille M; Vanel D; Albiter M; Le Cesne A; Bonvalot S; Le Péchoux C; Terrier P; Shapeero LG; Dromain C
    Eur J Radiol; 2009 Feb; 69(2):204-8. PubMed ID: 19046841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].
    Toyokawa T; Yamashita Y; Yamamoto A; Shimizu S; Inoue T; Kanazawa A; Tsukamoto T; Ikehara T; Nishiguchi Y
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):55-8. PubMed ID: 24423952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
    Bauer S; Hartmann JT; de Wit M; Lang H; Grabellus F; Antoch G; Niebel W; Erhard J; Ebeling P; Zeth M; Taeger G; Seeber S; Flasshove M; Schütte J
    Int J Cancer; 2005 Nov; 117(2):316-25. PubMed ID: 15900603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
    Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
    Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
    Lai IR; Hu RH; Chang KJ
    Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
    Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.
    Prenen H; Dumez H; Stefan C; Hoeben A; Wouters C; Van Lierde MA; Sciot R; van Oosterom AT; Peeters M; Polus M; Duck L; Gil T; Schöffski P
    Acta Gastroenterol Belg; 2006; 69(4):367-71. PubMed ID: 17343077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of imatinib-resistant GIST treated by sunitinib].
    Sakamoto Y; Akimoto H; Kojo M; Kawano H; Chinen Y; Morita K; Sugiyama M; Saeki H; Minami K; Soejima Y; Sakaguchi Y; Toh Y; Okamura T
    Gan To Kagaku Ryoho; 2011 May; 38(5):827-30. PubMed ID: 21566447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
    Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF
    Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
    Cheng CT; Tsai CY; Yeh CN; Chiang KC; Chen YY; Wang SY; Chen TW; Tseng JH; Jung SM; Chen TC; Yeh TS
    Anticancer Res; 2014 Nov; 34(11):6617-25. PubMed ID: 25368266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response evaluation of gastrointestinal stromal tumors.
    Choi H
    Oncologist; 2008; 13 Suppl 2():4-7. PubMed ID: 18434631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.
    De Giorgi U; Aliberti C; Benea G; Conti M; Marangolo M
    Clin Cancer Res; 2005 Sep; 11(17):6171-6. PubMed ID: 16144917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of rectal gastrointestinal stromal tumor in an elderly patient who was successfully treated with imatinib mesylate with no significant adverse events].
    Gomi K; Mihara M; Abe M; Ikeda Y; Shimada K; Maruyama K; Kajikawa S; Shirota H
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):103-6. PubMed ID: 24423962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
    Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG
    Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
    Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
    Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.